Treatment options in Alzheimer's disease: Maximizing benefit, managing expectations

被引:103
作者
Farlow, Martin R. [1 ]
Miller, Michael L. [2 ]
Pejovic, Vojislav [2 ]
机构
[1] Indiana Univ, Sch Med, Dept Neurol, Indianapolis, IN 46202 USA
[2] Prescott Med Commun Grp, Chicago, IL USA
关键词
Alzheimer's disease; cholinesterase inhibitors; Memantine; pharmacotherapy; combination therapy; antioxidants; Ginkgo biloba;
D O I
10.1159/000122962
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Alzheimer's disease ( AD) is becoming an increasingly heavy burden on the society of developed countries, and physicians now face the challenge of providing efficient treatment regimens to an ever-higher number of individuals affected by the disease. Currently approved anti-AD therapies - the cholinesterase inhibitors and the N-methyl-D-aspartate receptor antagonist memantine-offer modest symptomatic relief, which can be enhanced using combination therapy with both classes of drugs. Additionally, alternative therapies such as nonsteroidal anti-inflammatory drugs, vitamin E, selegiline, Ginkgo biloba extracts, estrogens, and statins, as well as behavioral and lifestyle changes, have been explored as therapeutic options. Until a therapy is developed that can prevent or reverse the disease, the optimal goal for effective AD management is to develop a treatment regimen that will yield maximum benefits for individual patients across multiple domains, including cognition, daily functioning, and behavior, and to provide realistic expectations for patients and caregivers throughout the course of the disease. This review provides a basic overview of approved AD therapies, discusses some pharmacologic and nonpharmacologic treatment strategies that are currently being investigated, and offers suggestions for optimizing treatment to fit the needs of individual patients. Copyright (c) 2008 S. Karger AG, Basel.
引用
收藏
页码:408 / 422
页数:15
相关论文
共 182 条
  • [71] BIOCHEMICAL ACTIONS OF L-DEPRENYL (SELEGILINE)
    LANGE, KW
    RIEDERER, P
    YOUDIM, MBH
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 56 (06) : 734 - 741
  • [72] Larson EB, 2006, ANN INTERN MED, V144, P73, DOI 10.7326/0003-4819-144-2-200601170-00004
  • [73] The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse
    Lim, GP
    Chu, T
    Yang, FS
    Beech, W
    Frautschy, SA
    Cole, GM
    [J]. JOURNAL OF NEUROSCIENCE, 2001, 21 (21) : 8370 - 8377
  • [74] Risk factors for Alzheimer's disease:: A prospective analysis from the Canadian Study of Health and Aging
    Lindsay, J
    Laurin, D
    Verreault, R
    Hébert, R
    Helliwell, B
    Hill, GB
    McDowell, I
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 2002, 156 (05) : 445 - 453
  • [75] Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond
    Lipton, SA
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (02) : 160 - 170
  • [76] Evidence-based psychological treatments for disruptive behaviors in individuals with dementia
    Logsdon, Rebecca G.
    McCurry, Susan M.
    Teri, Linda
    [J]. PSYCHOLOGY AND AGING, 2007, 22 (01) : 28 - 36
  • [77] Incidence of dementia in mild cognitive impairment in the Cardiovascular Health Study Cognition Study
    Lopez, Oscar L.
    Kuller, Lewis H.
    Becker, James T.
    Dulberg, Corinne
    Sweet, Robert A.
    Gach, H. Michael
    DeKosky, Steven T.
    [J]. ARCHIVES OF NEUROLOGY, 2007, 64 (03) : 416 - 420
  • [78] Brief screening tests for dementia
    Lorentz, WJ
    Scanlan, JM
    Borson, S
    [J]. CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2002, 47 (08): : 723 - 733
  • [79] Galantamine for Alzheimer's disease and mild cognitive impairment
    Loy, C
    Schneider, L
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2006, (01):
  • [80] Antioxidant vitamin intake and risk of Alzheimer disease
    Luchsinger, JA
    Tang, MX
    Shea, S
    Mayeux, R
    [J]. ARCHIVES OF NEUROLOGY, 2003, 60 (02) : 203 - 208